The synergistic role of Pu.1 and Fms in zebrafish osteoclast-reducing osteopetrosis and possible therapeutic strategies

Wei Liu,Qianqian Di,Kailun Li,Jing Li,Ning Ma,Zhibin Huang,Jiahao Chen,Sheng Zhang,Wenqing Zhang,Yiyue Zhang
DOI: https://doi.org/10.1016/j.jgg.2020.09.002
IF: 5.723
2020-09-01
Journal of Genetics and Genomics
Abstract:<p>Osteoclasts are bone-resorption cells of myeloid origin. Osteoclast defects can lead to osteopetrosis, a genetic disorder characterized by bone sclerosis for which there is no effective drug treatment. It is known that Pu.1 and Fms are key regulators in myelopoiesis, and their defects in mice can lead to reduced osteoclast numbers and consequent osteopetrosis. Yet, how Pu.1 and Fms genetically interact in the development of osteoclasts and the pathogenesis of osteopetrosis is still unclear. Here we characterized <em>pu.1</em><sup><em>G242D</em></sup>;<em>fms</em><sup><em>j4e1</em></sup> double-deficient zebrafish, which exhibited a greater deficiency of functional osteoclasts and displayed more severe osteopetrotic symptoms than the <em>pu.1</em><sup><em>G242D</em></sup> or <em>fms</em><sup><em>j4e1</em></sup> single mutants, suggesting a synergistic function of Pu.1 and Fms in the regulation of osteoclast development. We further demonstrated that Pu.1 plays a dominant role in osteoclastogenesis, while Fms plays a dominant role in osteoclast-maturation. Importantly, treatment with the drug retinoic acid significantly relieved the different degrees of osteopetrosis symptoms in these models by increasing the number of functional osteoclasts. Thus, we report the development of valuable animal models of osteopetrosis, and our results shed light on drug development for anti-osteopetrosis therapy.</p>
genetics & heredity,biochemistry & molecular biology
What problem does this paper attempt to address?